文献速递白血病

吉瑞替尼治疗复发/难治性FLT3突变阳性急性髓系白血病患者的3期ADMIRAL试验随访

Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
PubMed 文献 · Blood · 2022-01-01

3期ADMIRAL试验显示,复发/难治性FLT3突变阳性急性髓系白血病患者按2:1随机接受吉瑞替尼或挽救性化疗,吉瑞替尼组总生存优于挽救性化疗组。本次分析为初次分析后2年随访,中位随访37.1个月,吉瑞替尼组和挽救性化疗组中位总生存分别为9.3个月和5.6个月(HR 0.665;95%CI 0.518,0.853;双侧P=0.0013)。

要点

  • 吉瑞替尼组中位总生存9.3个月,挽救性化疗组5.6个月,HR 0.665(95%CI 0.518,0.853;P=0.0013)。
  • 2年估计生存率吉瑞替尼组20.6%(95%CI 15.8,26.0),挽救性化疗组14.2%(95%CI 8.3,21.6)。
  • 吉瑞替尼组第1至2年最常见关注不良事件为肝转氨酶升高,第2年发生率下降。

核心结论

  • 持续及造血干细胞移植后吉瑞替尼维持治疗可维持缓解且安全性稳定。
  • 延长吉瑞替尼治疗安全,且与优于挽救性化疗的生存相关。

研究设计与样本

  • 3期ADMIRAL试验(NCT02421939;研究ID:2215-CL-0301)的随访分析,初次分析后2年进行。
  • 患者为复发/难治性FLT3突变阳性急性髓系白血病,按2:1随机接受口服FMS样酪氨酸激酶3抑制剂吉瑞替尼或挽救性化疗。
  • 本次分析时中位生存随访37.1个月;吉瑞替尼组247例中203例死亡,挽救性化疗组124例中97例死亡;16例吉瑞替尼治疗患者仍在治疗中。

主要发现

  • 吉瑞替尼组和挽救性化疗组中位总生存分别为9.3个月和5.6个月(HR 0.665;95%CI 0.518,0.853;双侧P=0.0013)。
  • 2年估计生存率吉瑞替尼组为20.6%(95%CI 15.8,26.0),挽救性化疗组为14.2%(95%CI 8.3,21.6)。
  • 吉瑞替尼组复合完全缓解后2年累积复发率为75.7%,18个月后复发少见。
  • 吉瑞替尼组247例中49例、挽救性化疗组124例中14例存活≥2年;吉瑞替尼组26例存活≥2年且无复发,其中18例接受造血干细胞移植,16例在移植后重新开始吉瑞替尼维持治疗。
  • 吉瑞替尼治疗第1至2年最常见关注不良事件为肝转氨酶升高,第2年不良事件发生率下降。

临床怎么用

  • 原文结论认为持续及移植后吉瑞替尼维持治疗可维持缓解且安全性稳定。
  • 原文结论认为延长吉瑞替尼治疗安全,且与优于挽救性化疗的生存相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phase 3 ADMIRAL (NCT02421939; Study ID: 2215-CL-0301) trial showed superior overall survival in patients with relapsed/refractory FLT3-mutation-positive acute myeloid leukemia (AML) randomized 2:1 to receive the oral FMS-like tyrosine kinase 3 inhibitor gilteritinib vs those randomized to receive salvage chemotherapy (SC). Here we provide a follow-up of the ADMIRAL trial 2 years after the primary analysis to clarify the long-term treatment effects and safety of gilteritinib in these patients with AML. At the time of this analysis, the median survival follow-up was 37.1 months, with deaths in 203 of 247 and 97 of 124 patients in the gilteritinib and SC arms, respectively; 16 gilteritinib-treated patients remained on treatment. The median overall survival for the gilteritinib and SC arms was 9.3 and 5.6 months, respectively (hazard ratio, 0.665; 95% confidence interval [CI], 0.518, 0.853; two-sided P = .0013); 2-year estimated survival rates were 20.6% (95% CI, 15.8, 26.0) and 14.2% (95% CI, 8.3, 21.6). The gilteritinib-arm 2-year cumulative incidence of relapse after composite complete remission was 75.7%, with few relapses occurring after 18 months. Overall, 49 of 247 patients in the gilteritinib arm and 14 of 124 patients in the SC arm were alive for ≥2 years. Twenty-six gilteritinib-treated patients remained alive for ≥2 years without relapse; 18 of these patients underwent transplantation (hematopoietic stem cell transplantation [HSCT]) and 16 restarted gilteritinib as post-HSCT maintenance therapy. The most common adverse events of interest during years 1 and 2 of gilteritinib therapy were increased liver transaminase levels; adverse event incidence decreased in year 2. Thus, continued and post-HSCT gilteritinib maintenance treatment sustained remission with a stable safety profile. These findings confirm that prolonged gilteritinib therapy is safe and is associated with superior survival vs SC. This trial was registered at www.clinicaltrials.gov as #NCT02421939.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Perl AE, Larson RA, Podoltsev NA, et al. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022. PMID: 35081255. doi:10.1182/blood.2021011583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。